(KRMD) KORU Medical Systems, Inc. ANSOFF Analysis Research

Precision flow rate tubing reorder growth is classic market penetration for KORU Medical Systems, Inc. It drives repeat buying from existing FREEDOM system users in ambulatory infusion, where the installed base already uses the tubing as a consumable. In 2025, KORU’s annual revenue was centered on the same core ecosystem, so higher refill frequency should lift same-market sales.

• Repeat use from current patients
• Supports FREEDOM system sales
• Expands share in ambulatory infusion

Because tubing is replaced regularly, even small reorder gains can raise revenue without needing new market entry. That makes this a low-risk growth lever inside KORU Medical Systems, Inc.'s current customer base.

KORU Medical Systems, Inc. can capture more share in current markets by pushing the same patient base through two active routes: medical device distributors and online channels. That widens access without changing the core product, so order frequency can rise inside the same customer set. In Ansoff terms, this is market penetration, not new-market expansion.

• Uses existing distributor network
• Expands reach through online orders
• Targets the same customer base
• Lifts volume without new products

Localized training materials help KORU Medical Systems, Inc. enter new markets with its current products by cutting adoption friction. KORU Medical Systems already gives education to healthcare professionals, patients, and patient advocates, so translating and adapting that content can speed uptake of the same infusion systems in new territories.

• Lower onboarding friction
• Support faster market entry
• Reuse existing education assets
• Improve user confidence locally

Broader ambulatory infusion provider coverage is a market-development move: KORU Medical Systems, Inc. is selling the same systems into more provider accounts, not changing the therapy itself. That can raise volume faster because each new ambulatory infusion provider expands reach across the same subcutaneous and IV use cases.

It fits a low-change, lower-risk path: existing products stay in place, while the addressable customer map widens across clinics, home-infusion groups, and regional providers. The upside is better penetration of the ambulatory infusion base; the limit is that growth depends on winning more accounts, not on new therapy demand.

• New provider accounts, same therapy category.
• Broader reach without product redesign.
• Growth comes from more locations served.
• Depends on sales coverage and provider adoption.

Accessory kits for FREEDOM60 and FreedomEdge fit KORU Medical Systems, Inc. in the product development quadrant because they add supporting items to an existing platform, not a new therapy. The base systems already depend on multiple components, so bundled kits can make setup simpler for providers and patients and raise per-treatment convenience.

This is a low-risk extension of an installed base used for subcutaneous immunoglobulin and other infusion workflows. By packaging needed parts together, KORU Medical Systems, Inc. can reduce missing-item delays and support repeat use without changing the core pump design.

• Extends current product lines
• Uses existing system components
• Improves clinic and home convenience
• Can support repeat accessory sales

Expanded education and training packages turn KORU Medical Systems, Inc. learning content into a paid product layer, not just support material. That fits the current portfolio well because KORU already trains 3 user groups: healthcare professionals, patients, and patient advocates.

More structured packages can speed adoption of the current infusion systems by reducing setup errors, improving confidence, and shortening time to first use. This is a low-capex way to deepen customer stickiness and can lift repeat orders without changing the core device.

For an Ansoff lens, this is product development with a clear service add-on: same customer base, richer offer, higher value per account. If KORU bundles device onboarding, refreshers, and role-based modules, it can make education a measurable revenue stream and a stronger moat.

• Turns training into a product.
• Targets 3 existing user groups.
• Boosts adoption of current devices.
• Raises stickiness without new hardware.

Therapy-adjacent mechanical delivery would stretch KORU Medical Systems, Inc.’s infusion know-how into new uses beyond ambulatory pumps, using the same mobile-device design base. In FY2025, the company’s net sales were about $36 million, so even small wins in adjacent channels could matter. A move into non-core delivery settings would diversify revenue without building a new platform from scratch.

• Uses existing mechanical infusion expertise
• Targets new therapy-adjacent use cases
• Diversifies beyond ambulatory infusion
• Fits a FY2025 revenue base near $36 million

International service and support bundles fit KORU Medical Systems, Inc.’s diversification play: they pair new offerings with markets beyond its current base, while using the company’s existing international footprint. That shifts value from one-time device shipment revenue toward recurring service revenue, which can smooth sales volatility.

This matters because KORU already sells outside the U.S., so bundled training, maintenance, and clinical support can deepen account value without needing a new device launch.

• New offer: recurring service bundle
• New market: broader international accounts
• Benefit: less dependence on device shipments